Literature DB >> 1659471

Subtypes of Epstein-Barr virus in human immunodeficiency virus-associated non-Hodgkin lymphoma.

M J Boyle1, W A Sewell, T B Sculley, A Apolloni, J J Turner, C E Swanson, R Penny, D A Cooper.   

Abstract

Biopsy samples obtained from 20 patients with human immunodeficiency virus (HIV)-associated non-Hodgkin lymphoma (NHL) were assessed for evidence of Epstein-Barr virus (EBV) and HIV sequences. DNA was extracted from formalin-fixed, paraffin-embedded NHL tissue and specific viral gene sequences were sought using the polymerase chain reaction (PCR). EBV sequences were found in 10 NHL samples (50%), with five tumors showing A-type and five B-type sequences. By serologic testing, 18 of 19 patients had antibodies to EBV, with 14 patients having antibodies to A-type EBV and 11 to B-type EBV. Serology confirmed the high prevalence of type B EBV in HIV-infected patients, but was not a reliable indicator of the EBV subtype present in the lymphomas. HIV sequences were present in biopsy tissue but at a level consistent with an origin from bystander HIV-infected cells. All 20 patients were negative by enzyme-linked immunosorbent assay for antibodies to human T-cell leukemia virus-type I. The high prevalence of type B EBV in these tumors is similar to the findings in endemic Burkitt's lymphoma, where 40% of the tumors have type B viral sequences. In normal populations, type B EBV is rarely found outside the nasopharynx. These studies support the hypothesis that EBV is an important cofactor in NHL in HIV-infected persons. The finding that B-type EBV is present in 25% of HIV-associated NHL suggests that this EBV subtype may be an important human pathogen with a wider geographic distribution than originally thought.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1659471

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

1.  Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-kappa B activity.

Authors:  M L Hammarskjöld; M C Simurda
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

2.  Epstein-Barr virus in malignancies in renal transplant recipients in Japan.

Authors:  Y Hoshida; Y Tomita; M Ohsawa; X Ning; K Aozasa
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

3.  The evolution of Epstein-Barr virus inferred from the conservation and mutation of the virus glycoprotein gp350/220 gene.

Authors:  Asako Kawaguchi; Kyosuke Kanai; Yukio Satoh; Chizu Touge; Keiko Nagata; Takeshi Sairenji; Yoshitsugu Inoue
Journal:  Virus Genes       Date:  2009-01-20       Impact factor: 2.332

4.  Epidemiology of infection with Epstein-Barr virus types 1 and 2: lessons from the study of a T-cell-immunocompromised hemophilic cohort.

Authors:  Q Y Yao; D S Croom-Carter; R J Tierney; G Habeshaw; J T Wilde; F G Hill; C Conlon; A B Rickinson
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

Review 5.  The Epstein-Barr virus and its association with human cancers.

Authors:  K R Baumforth; L S Young; K J Flavell; C Constandinou; P G Murray
Journal:  Mol Pathol       Date:  1999-12

6.  Isolation of intertypic recombinants of Epstein-Barr virus from T-cell-immunocompromised individuals.

Authors:  Q Y Yao; R J Tierney; D Croom-Carter; G M Cooper; C J Ellis; M Rowe; A B Rickinson
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

7.  Frequency of multiple Epstein-Barr virus infections in T-cell-immunocompromised individuals.

Authors:  Q Y Yao; R J Tierney; D Croom-Carter; D Dukers; G M Cooper; C J Ellis; M Rowe; A B Rickinson
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

8.  Epstein-Barr virus in pyothorax-associated pleural lymphoma.

Authors:  M Fukayama; T Ibuka; Y Hayashi; T Ooba; M Koike; S Mizutani
Journal:  Am J Pathol       Date:  1993-10       Impact factor: 4.307

Review 9.  Molecular pathology of AIDS-related lymphomas. Biologic aspects and clinicopathologic heterogeneity.

Authors:  G Gaidano; C Pastore; C Lanza; U Mazza; G Saglio
Journal:  Ann Hematol       Date:  1994-12       Impact factor: 3.673

Review 10.  The molecular genetics of post-transplantation lymphoproliferative disorders.

Authors:  D M Knowles
Journal:  Springer Semin Immunopathol       Date:  1998
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.